drug development

Kazia in-licenses SETDB1 epigenetic platform from QIMR Berghofer to develop immunotherapy-resistant cancer treatment.

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.

Aardvark Therapeutics ($AARD) plummeted 56% after pausing Phase 3 HERO trial for ARD-101 due to cardiac safety concerns, contradicting prior safety assurances.

Rosen Law Firm urges Soleno Therapeutics investors with $100K+ losses to join securities lawsuit alleging concealed DCCR drug safety concerns. Lead plaintiff deadline: May 5, 2026.

Fortrea unveiled Fortrea Intelligent Technology, an AI-powered suite automating clinical trial workflows and enhancing productivity for research centers and investigators.

Fortrea launches AI-powered clinical trial platform FIT to automate operations and accelerate drug development timelines for pharmaceutical sponsors and research sites globally.

Fortrea unveiled Fortrea Intelligent Technology, an AI-driven solution suite designed to automate workflows and provide real-time insights across clinical trial operations.

Disc Medicine stock tumbled 30% after FDA rejected bitopertin drug application, prompting securities fraud investigation by Pomerantz LLP.

ORIC Pharmaceuticals surged then crashed 25% after-hours despite publishing positive Phase 1b trial results for cancer therapy candidate rinzimetostat, highlighting biotech market skepticism.

Waste Management and Gilead Sciences offer attractive dividend-growth opportunities as pullbacks from Middle East tensions create entry points for AI-driven productivity investors.

Alvotech files 2025 annual report with SEC, reporting five marketed biosimilars and nine additional candidates in development across therapeutic areas.

Alvotech files 2025 annual SEC report with five marketed biosimilars and nine pipeline candidates supported by global partnerships.

Alvotech files 2025 annual report showing five approved biosimilars and nine pipeline candidates across multiple therapeutic areas, positioning the company amid rapid biosimilar market growth.

Pfizer pursues GLP-1 market opportunity through acquisition after internal failure, offering 6.2% dividend yield amid 50% stock decline from 2021 peaks.

AstraZeneca's tozorakimab shows positive Phase 3 COPD data, reducing exacerbations versus placebo. Stock rises 3.68% premarket; company forecasts $3-5B peak sales.

Novartis to acquire allergy biotech Excellergy for up to $2 billion, gaining first-in-class ECRI technology and lead candidate Exl-111 currently in Phase 1 trials.

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.

Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.

Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.